H.C. Wainwright analyst Yi Chen initiated coverage of Alpha Tau Medical with a Buy rating and $9 price target. Alpha is a clinical-stage medical device company focused on the development of short-range alpha particle based radiation therapy for solid tumors, the analyst tells investors in a research note. The analyst says the company’s diffusing alpha-emitting radiation therapy technology is differentiated in that it leverages therapeutic properties of alpha particles while overcoming the traditional shortcomings of alpha radiation’s limited range.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DRTS:
- Alpha Tau, JGH announce Alpha DaRT treatment of first patient
- Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
- Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
- Alpha Tau Medical confirms no direct exposure to Silicon Valley Bank
- Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
